BioTech IP Review

• Patent Number: U.S. Patent No. 11,590,229 B2
• Issue Date: February 28, 2023
• Filing / Priority Dates: Claims priority to provisional filings circa December 7, 2011 and April 12, 2012 (typical for this family of patents)
• Assignee: Alnylam Pharmaceuticals, Inc.

What This Patent Covers

This patent protects a class of biodegradable lipid molecules and related lipid particle compositions designed to deliver active agents such as nucleic acids (e.g., siRNA or mRNA) into cells. Specifically:

• Cationic and PEG-lipids that contain biodegradable groups in their hydrophobic chains, which help form lipid nanoparticles (LNPs) capable of encapsulating therapeutic nucleic acids for delivery into target cells.
• LNP compositions used to deliver RNA-based drugs—with improved tolerability and safety because the lipids biodegrade in vivo after delivering their cargo.
• Methods of delivery, i.e., administering these lipid particles with active agents to treat diseases by enabling cellular uptake of RNA molecules.

Why This Patent is Important

• It represents critical intellectual property in RNA delivery technology, a core part of Alnylam’s platform that enables its RNAi therapeutics and underpins future innovation.
• The patent family has been asserted in litigation (e.g., against major vaccine developers) because it covers lipid nanoparticle innovations allegedly used in mRNA vaccine delivery.
• Its issuing strengthened Alnylam’s IP estate as RNA-based medicines expand commercially and technologically.

Summary: U.S. Patent No. 11,590,229 protects biodegradable lipid components and compositions for delivering nucleic acid therapies, forming a cornerstone of Alnylam’s delivery technology and helping secure its competitive position in the RNA therapeutics market.